CoChat

Cetuximab strongly enhances immune cell infiltration into liver metastatic sites in colorectal cancer

Open access
Inoue, Yuka, Hazama, Shoichi, Suzuki, Nobuaki, Tokumitsu, Yukio, Kanekiyo, Shinsuke, Tomochika, Shinobu, Tsunedomi, Ryouichi, Tokuhisa, Yoshihiro, Iida, Michihisa, Sakamoto, Kazuhiko, Takeda, Shigeru, Ueno, Tomio, Yoshino, Shigefumi, Nagano, Hiroaki · 2017 · Cancer Science
Cited by 67

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Cetuximab has activity against colorectal cancers. Recent studies demonstrated that cetuximab induces antibody‐dependent cell‐mediated cytotoxicity via immune cells, and a new immune‐related mechanism of inducing immunogenic cell death. This study aimed to evaluate the immune responses induced by cetuximab in tumor microenvironments at liver metastasis sites of metastatic colorectal cancer patients. We assessed immune cell infiltration in the liver metastatic sites of 53 colorectal cancer patients. These patients were divided into three groups according to the treatment before operation: chemotherapy with cetuximab, chemotherapy without cetuximab, and no chemotherapy. The inflammatory cells in the liver metastatic sites were assessed by hematoxylin–eosin staining, focusing on the invasive margin. The overall inflammatory reaction and number of lymphoid cells were assessed with a four‐point scoring system. We then assessed immune cell infiltration (CD 3, CD 8 and CD 56) in 15 liver metastatic sites. Hematoxylin–eosin staining demonstrated more inflammatory cells in the chemotherapy with cetuximab group than in the other groups (P < 0.001). Of note, inflammatory cells were found in intratumoral areas, and the destruction of cancer cell foci was observed in the chemotherapy with cetuximab group. Moreover, a higher infiltration of CD 3+ (P = 0.003), CD 8+ (P = 0.003) and CD 56+ (P = 0.001) cells was observed in the chemotherapy with cetuximab group than in the other groups. These results suggest that cetuximab might have an immune‐enhancing effect. As such, the immune‐related mechanism of action of cetuximab may enhance the efficacy of combination therapy, such as chemotherapy and immunotherapy using therapeutic peptides.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/cas.13162

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 67

Metadata

Authors
Inoue, Y., Hazama, S., Suzuki, N., Tokumitsu, Y., Kanekiyo, S., Tomochika, S., Tsunedomi, R., Tokuhisa, Y., Iida, M., Sakamoto, K., Takeda, S., Ueno, T., Yoshino, S., & Nagano, H.
Venue
Cancer Science
Publisher
Wiley
Published
2017-03
Volume
108
Issue
3
Pages
455-460
ISSN
  • 1347-9032 (ISSN-L)
  • 1349-7006
OpenAlex
W2573449099
Cited by
67
References
5
FWCI
2.91
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cetuximab strongly enhances immune cell infiltration into liver metastatic sites in colorectal cancer. https://app.cochat.ai/papers/10.1111/cas.13162
The paper
Inoue, Y., Hazama, S., Suzuki, N., Tokumitsu, Y., Kanekiyo, S., Tomochika, S., Tsunedomi, R., Tokuhisa, Y., Iida, M., Sakamoto, K., Takeda, S., Ueno, T., Yoshino, S., & Nagano, H. (2017). Cetuximab strongly enhances immune cell infiltration into liver metastatic sites in colorectal cancer. Cancer Science. https://doi.org/10.1111/cas.13162

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.